This post was originally published on this site Adding an assessment of a woman’s clinical risk to Genomic Health‘s genomic test Oncotype DX to estimate the likelihood of breast cancer recurrence may spare more young women from having to undergo chemotherapy after surgery than originally thought. These findings come from a secondary analysis of the…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
Tyvyt Effective, Safe in Previously Treated Patients with Hodgkin’s Lymphoma, Phase 2 Trial Shows
This post was originally published on this site Treatment with Tyvyt (sintilimab injection) was found safe and eased the tumor burden or led to cancer disappearance in nearly 3 out of 10 patients with relapsed or refractory classical Hodgkin’s lymphoma, according to follow-up results of a Phase 2 clinical trial in China. Trial findings, “Sintilimab…
Keytruda Improves Survival of Patients with Recurrent or Metastatic Head, Neck Cancer, Phase 3 Trial Shows
This post was originally published on this site First-line treatment with Keytruda (pembrolizumab) in combination with chemotherapy prolongs the survival of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC), compared to standard of care treatment, a final analysis of a Phase 3 trial shows. The findings were presented during an oral presentation,…
How a $100 Bill Brings Me Peace of Mind
This post was originally published on this site I could smell cleanliness when I opened my front door. Lemon. Pine. The glorious absence of dust. It’s that elusive moment right after my housecleaners leave and my home looks like it does in my imagination: orderly and spotless. My crockpot hints that dinner is on the…
Clinical Trial Results Suggest Isatuximab Improves Survival in People with RRMM
This post was originally published on this site Isatuximab, a potential therapeutic antibody, can improve survival in relapsed/refractory multiple myeloma patients being given a standard treatment consisting of Pomalyst (pomalidomide) and dexamethasone (brand names include Decadron and Dexpak), results of a pivotal Phase 3 clinical trial suggest. The data were presented at the 2019 annual meeting of the American…
Triple Therapy Combo Effective in Treating DLBCL Subtype, Data Suggest
This post was originally published on this site People with the non-germinal center subtype of diffuse large B-cell lymphoma (non-GCB DLBCL) respond well to initial treatment with Rituxan (rituximab), Imbruvica (ibrutinib), and Revlimid (lenalidomide) — so well that chemotherapy, the standard of treatment, might not be necessary in some cases. Results from the Smart Start…
Imfinzi Still Improving Survival Rates in Advanced NSCLC Patients, PACIFIC Update Shows
This post was originally published on this site AstraZeneca‘s Imfinzi (durvalumab) continues to demonstrate superior overall survival compared to placebo when given to patients with stage III, inoperable non-small-cell lung cancer (NSCLC) whose disease did not progress after platinum-based chemotherapy and radiation therapy. That finding comes from the three-year data update of the company’s randomized, blinded PACIFIC Phase 3…
Long-term Data Continue to Support Perjeta Regimen for HER2-positive Metastatic Breast Cancer
This post was originally published on this site End-of-study data from the CLEOPATRA trial supports the long-term efficacy of Genentech‘s Perjeta (pertuzumab) plus Herceptin (trastuzumab) and docetaxel chemotherapy for patients with previously untreated HER2-positive metastatic breast cancer. Patients on the Perjeta combination regimen lived a median 16.3 months longer, compared with the control group not receiving Perjeta,…
Immune Checkpoint Molecules Have Prognostic Value in Ovarian Cancer, Study Reports
This post was originally published on this site The immune checkpoint molecules PD-L1 and TIM-3 have prognostic value in people with ovarian cancer who have not yet received chemotherapy. But while low levels of TIM-3 were linked to longer survival rates, a study unexpectedly showed that high levels of PD-L1 predicted better patient survival. The…
Similar Efficacy and Safety Seen Between Under-the-Skin Formulation and Intravenous Darzalex for Myeloma, Phase 3 Trial Shows
This post was originally published on this site An under-the-skin formulation of daratumumab is as effective as its intravenous delivery — marketed as Darzalex — at easing tumor burden and has comparable safety in adults with relapsed or refractory multiple myeloma, according to a Phase 3 trial. Trial results were presented in a study, “Efficacy…
Adcetris Combo Continues to Show Better Results Than Chemotherapy Alone, Phase 3 Update Reveals
This post was originally published on this site Seattle Genetics‘ Adcetris (brentuximab vedotin) in combination with standard chemotherapy continues to show better clinical activity than bleomycin plus standard chemotherapy, as a front-line treatment for patients with Hodgkin’s lymphoma, updated Phase 3 data shows. Three-year data from the company’s randomized, open-label ECHELON-1 Phase 3 trial (NCT01712490) was…
Add-on Xtandi Prolongs Survival in Metastatic Hormone-sensitive PC, Trial Shows
This post was originally published on this site Treatment with Xtandi (enzalutamide) and testosterone suppression prolonged the survival of men with metastatic hormone-sensitive prostate cancer in comparison with standard of care, according to early findings of a large Phase 3 trial. The study, “Overall survival (OS) results of a phase III randomized trial of standard-of-care…